{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["belzutifan"]],"indication":"advanced solid tumors","name":"LITESPARK-001","nct_id":"NCT02974738","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=litespark-001-nct02974738. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Drug: PART 1A: Belzutifan for the treatment of advanced solid tumors\n\nBelzutifan inhibits HIF-2α and is a novel approach to treatment of solid tumors.","label":"Part 1A","type":"EXPERIMENTAL"},{"description":"Drug: PART 1B: Belzutifan for the treatment of advanced ccRCC\n\nBelzutifan inhibits HIF-2α and is a novel approach to treatment of ccRCC.","label":"Part 1B","type":"EXPERIMENTAL"},{"description":"Drug: Part 2: Belzutifan for the treatment of other specified solid tumors\n\nBelzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors.","label":"Part 2","type":"EXPERIMENTAL"},{"description":"Drug: Part 2A: Belzutifan for the treatment of patients with recurrent GBM who have been previously treated with radiation therapy and temozolomide\n\nBelzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors.","label":"Part 2A","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors","Solid Tumor","Solid Carcinoma","Solid Tumor, Adult","ccRCC","RCC, Clear Cell Adenocarcinoma","RCC","Kidney Cancer","Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma, Metastatic","Renal Cell Carcinoma Recurrent","Renal Cell Carcinoma, Clear Cell Adenocarcinoma","Glioblastoma","Glioblastoma, Adult","GBM","Glioblastoma Multiforme"],"enrollment":{"count":120,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Belzutifan","otherNames":["PT2977 Tablets, PT-2977, HIF-2α inhibitor, MK-6482","WELIREG™"],"type":"DRUG"}],"last_update":"2026-10-26","lead_sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","official_title":"A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2018-01-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"maximum tolerated dose (MTD)","timeFrame":"3 Weeks"}],"references":[{"citation":"Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Dror Michaelson M, Appleman LJ, Roy A, Perini RF, Liu Y, Choueiri TK. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024 Jan;196:113434. doi: 10.1016/j.ejca.2023.113434. Epub 2023 Nov 15.","pmid":"38008031","type":"DERIVED"},{"citation":"Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E. Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.","pmid":"33888901","type":"DERIVED"}],"start_date":{"date":"2016-12-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","url":"https://clinicaltrials.gov/study/NCT02974738"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/litespark-001-nct02974738"}